AI Article Synopsis
- The study aimed to assess how high-dose estrogen treatment affects various IGF components in girls with constitutional tall stature.
- Blood samples were collected before and after 3 months of estrogen treatment to analyze changes in IGF-I, IGF-II, and IGFBPs.
- Results showed that total IGF-I decreased during treatment but returned to previous levels after stopping, indicating that estrogen influences IGF levels primarily through a reduction in synthesis rather than changes in IGFBP levels.
Article Abstract
Objective: To investigate the effect of high-dose oestrogen treatment on IGF-I, IGF-II, free-dissociable IGF-I and the IGF-binding proteins (IGFBP)-2 to -6 in girls with constitutional tall stature.
Methods: In patient cohort 1, blood samples were drawn before and after 3 months of daily oral treatment with 0.1 mg ethinyloestradiol. In cohort 2, samples were collected at the end of the treatment period and 3 to 6 months afterwards. IGFs and IGFBPs were analysed by specific immunoassays and by Western ligand blot.
Results: Total IGF-I decreased significantly on oestrogen treatment and increased again after oestrogen withdrawal. Ligand blot analysis showed a clear reduction in a 34 kDa band, corresponding to IGFBP-2, and a strong induction of a 24 kDa band, corresponding to the non-glycosylated form of IGFBP-4. These changes were confirmed by specific immunological methods. The serum levels of IGFBP-3, IGFBP-5 and IGFBP-6 remained unchanged during the first 3 months of treatment. In cohort 2, IGFBP-3 and IGFBP-6 increased after oestrogen withdrawal. Free-dissociable IGF-I fell to 35+/-4% during oestrogen therapy and rose again when the treatment was stopped.
Conclusions: Oestrogens modulate the serum concentrations of several components of the IGF system. The fall in total IGF-I is not explained by a decrease in IGFBPs but probably results from a decreased synthesis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1530/eje.0.1460823 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A high-throughput platform for single-molecule tracking identifies drug interaction and cellular mechanisms.
Elife
January 2025
Eikon Therapeutics Inc, Hayward, United States.
The regulation of cell physiology depends largely upon interactions of functionally distinct proteins and cellular components. These interactions may be transient or long-lived, but often affect protein motion. Measurement of protein dynamics within a cellular environment, particularly while perturbing protein function with small molecules, may enable dissection of key interactions and facilitate drug discovery; however, current approaches are limited by throughput with respect to data acquisition and analysis.
View Article and Find Full Text PDFBreast Cancer Susceptibility Gene Sequence Variations and Development of Contralateral Breast Cancer.
JAMA Netw Open
December 2024
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Importance: Heterogeneity in development of estrogen receptor (ER)-specific first primary breast cancer exists due to deleterious germline variants in moderate- to high-penetrance breast cancer susceptibility genes, but it is unknown if these associations occur in ER-specific CBC.
Objective: To determine the association of deleterious germline variants in breast cancer susceptibility genes with ER-specific CBC development and whether ER status of the first primary breast cancer modifies these associations.
Design, Setting, And Participants: This case-control study included CBC cases and matched unilateral breast cancer controls from The Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study, a population-based case-control study.
Developing Topics.
Alzheimers Dement
December 2024
Brighton & Sussex Medical School, Brighton, United Kingdom.
Background: Reported effects of Hormone Replacement Therapy (HRT) on late-life neurodegenerative disease are inconsistent. Variability in the timing and formulation of HRT, plus whether an individual carries an Apolipoprotein (APOE) e4 genetic risk variant for Alzheimer's Disease (AD), likely contribute to conflicting results. Additionally, whilst many studies have focused exclusively on the effects of exogenous oestrogen, the inclusion of testosterone in HRT appears protective against AD pathology, specifically in APOE e4 carriers.
View Article and Find Full Text PDFDeveloping Topics.
Alzheimers Dement
December 2024
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Background: Hormone therapy (HT) is often used to manage symptoms related to menopause, but its longer-term effects on depressive symptoms in older women remains unclear. Previous literature reports inconclusive results on whether HT use is protective against or associated with increased depressive symptoms over time in older women. The objective of this study was to examine the associations of self-reported HT use with baseline and longitudinal later life depressive symptoms.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
B.S.A. College of Engineering and Technology, Mathura, Uttar Pradesh, India.
Background: Cognitive dysfunction emerges as a manifestation of reduced estrogen levels following ovariectomy in an individual. However, the conventional use of estrogen replacement therapy could increase the risk of breast cancer and thromboembolism. Icariin is a natural compound that has been reported to be a neuroprotective agent against dementia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!